Cargando…

Safety and efficacy of fimasartan with essential hypertension patients in real world clinical practice: data from a post marketing surveillance in Korea

The safety and efficacy of fimasartan have been evaluated through post-marketing surveillance in real world clinical practice. The multi-center, prospective, open-label and non-interventional study. A total of 3,945 patients (3,729 patients for safety assessment and 3,473 patients for efficacy asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Su-Eun, Jeong, Seung Hee, Kang, Hye Jeong, Hong, Myung Sook, Paek, Eunah, Cho, Hijung, Choe, Seong Choon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Clinical Pharmacology and Therapeutics 2018
Materias:	PMS Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989236/ https://www.ncbi.nlm.nih.gov/pubmed/32055561 http://dx.doi.org/10.12793/tcp.2018.26.3.118

Ejemplares similares

Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)
por: Oh, Dong Joo, et al.
Publicado: (2018)

Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
por: Rhee, Moo-Yong, et al.
Publicado: (2015)

Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial
por: Kang, Min-gu, et al.
Publicado: (2019)

24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
por: Lee, Hae-Young, et al.
Publicado: (2017)

Fimasartan: A new armament to fight hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension
por: Shin, Mi-Seung, et al.
Publicado: (2016)

Fimasartan for Remodeling after Myocardial Infarction
por: Lim, Byung-Kwan, et al.
Publicado: (2019)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Comparative efficacy and safety of fimasartan in patients with hypertension: A network meta‐analysis of randomized controlled trials
por: Seo, Suk Min, et al.
Publicado: (2022)

A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy
por: Jeon, Eun-Seok, et al.
Publicado: (2022)

Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats
por: Lim, Hyo-Jeong, et al.
Publicado: (2013)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study
por: Cho, Eun Joo, et al.
Publicado: (2019)

Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb Study): An Open-Label Observational Study
por: Park, Jeong Bae, et al.
Publicado: (2013)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
por: Kang, Woo Youl, et al.
Publicado: (2020)

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
por: Kim, Song-Yi, et al.
Publicado: (2016)

Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis
por: Kim, Choon OK, et al.
Publicado: (2017)

Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis
por: Cho, Jang-Hee, et al.
Publicado: (2018)

Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2018)

Effects of Fimasartan/Amlodipine Fixed-Dose Combination on Left Ventricular Systolic Function and Infarct Size in Rat Myocardial Infarction Model
por: Kim, Han Byul, et al.
Publicado: (2019)

Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
por: Hong, Keun-Sik, et al.
Publicado: (2021)

Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
por: Kim, Hyeongyeong, et al.
Publicado: (2021)

National post-market surveillance assessment of veterinary medicines in Korea during the past decade
por: Kang, JeongWoo, et al.
Publicado: (2017)

Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain
por: Kim, Chi Kyung, et al.
Publicado: (2015)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
por: Gu, Namyi, et al.
Publicado: (2016)

Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved In Situ Absorption Method in Rats
por: Kim, Tae Hwan, et al.
Publicado: (2018)

The world ginseng market and the ginseng (Korea)
por: Baeg, In-Ho, et al.
Publicado: (2013)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
por: Sim, Doo Sun, et al.
Publicado: (2015)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
por: Choi, Yewon, et al.
Publicado: (2018)

The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics
por: Kim, Changsoo, et al.
Publicado: (2014)

Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats
por: Kim, Tae Hwan, et al.
Publicado: (2016)

Gender-specific differences in the incidence of microalbuminuria in metabolic syndrome patients after treatment with fimasartan: The K-MetS study
por: Park, Jeong Bae, et al.
Publicado: (2017)

Fimasartan reduces neointimal formation and inflammation after carotid arterial injury in apolipoprotein E knockout mice
por: Kim, Jong-Ho, et al.
Publicado: (2019)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

Therapeutic Effect of Fimasartan in a Rat Model of Myocardial Infarction Evaluated by Cardiac Positron Emission Tomography with [(18)F]FPTP
por: Park, Hyukjin, et al.
Publicado: (2019)

Partnerships supporting policies: A social marketing case study of mask supply solutions in South Korea during the COVID-19 pandemic
por: Paek, Hye-Jin, et al.
Publicado: (2023)

Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)
por: Chung, Woo-Baek, et al.
Publicado: (2020)

Widening Social Inequalities in Cancer Mortality of Children Under 5 Years in Korea
por: Son, Mia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5hontgjbuc2ho3bc5jubb3sifo